The project LIVERAIM started on 1 March 2024
The project LIVERAIM, A Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy, started on 1 March 2024 and lasts until 28 February 2030.
In the LIVERAIM project, consortium is structured of renowned clinical centers and industry partners, including SMEs, with extensive expertise in liver disease, with the aim of designing and validating a population screening platform to be used across Europe. The consortium consists of 31 institutions from 11 countries. The project budget is €24,789,953.89.
Project Manager of the Croatian Partner, School of Medicine University of Zagreb, is assistant professor Ivica Grgurević.
The goal is to identify liver disease early and apply personalized therapy. A large number of existing biomarkers will be tested for fibrosis prediction accuracy using plasma samples from a biobank of 40,000 participants from previous cohorts of the EU-funded LiverScreen project H2020. LIVERAIM will develop an AI-based biomarker screening platform for personalized early diagnosis of fibrosis. A cohort of 100,000 participants from 6 representative EU countries will be included in the project. The platform will be linked to tailored, personalized therapeutic interventions to stop the progression of fibrosis. With LIVERAIM, early diagnosis and personalized intervention can stop the progression of liver disease, help reduce morbidity and mortality, and enable economic and health equity for all.